Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Industry, Sector and Symbol:
Capitalization:- Market Cap: C$62.14 million
- Outstanding Shares: 121,836,000
Average Prices:- 50 Day Moving Avg: C$0.51
- 200 Day Moving Avg: C$0.56
- 52 Week Range: C$0.19 - C$1.13
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: C$0.06 per share
- Price / Book: 8.50
Profitability:- EBIDTA: ($13,310,000.00)
- Return on Equity: -157.09%
- Return on Assets: -111.18%
Misc:- Average Volume: 366,338 shs.
- Short Ratio: 1.33
Frequently Asked Questions for Oncolytics Biotech (TSE:ONC)
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the Tornton Stock Exchange (TSX) under the ticker symbol "ONC."
Where is Oncolytics Biotech's stock going? Where will Oncolytics Biotech's stock price be in 2017?
2 brokerages have issued 12-month target prices for Oncolytics Biotech's shares. Their predictions range from C$1.50 to C$1.50. On average, they expect Oncolytics Biotech's stock price to reach C$1.50 in the next year. View Analyst Ratings for Oncolytics Biotech.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include PHX Energy Services Corp (PHX), TransGlobe Energy (TGL), Redknee Solutions (RKN), Gabriel Resources Ltd (GBU), Newalta (NAL), Tree Island Steel (TSL), Western Energy Services Corp (WRG), Petrus Resources Ltd (PRQ), Temple Hotels (TPH), Aralez Pharmaceuticals (ARZ), Oryx Petroleum Co. Ltd (OXC), Journey Energy (JOY), Etrion SA (ETX), RMP Energy (RMP), Concordia International Corp (CXR), Primero Mining Corp (P), Fortress Paper (FTP) and Colabor Group (GCL).
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Wayne F. Pisano, Chairman of the Board
- Matthew C. Coffey Ph.D., President, Chief Executive Officer, Chief Operating Officer, Director
- Kirk J. Look, Chief Financial Officer
- George M. Gill M.D., Senior Vice President - Regulatory Affairs & Chief Safety Officer
- Mary Ann Dillahunty J.D., Vice President - Intellectual Property
- Andres A. Gutierrez M.D., PhD., Chief Medical Officer
- Alan J. Tuchman M.D., Chief Neuro Oncology Research Officer
- Angela Frances Holtham, Director
- Edwin Levy Ph.D., Director
- J. Mark Lievonen, Director
How do I buy Oncolytics Biotech stock?
Shares of Oncolytics Biotech and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Oncolytics Biotech's stock price today?
One share of Oncolytics Biotech stock can currently be purchased for approximately C$0.51.
MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Oncolytics Biotech (TSE:ONC) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | C$1.50 |
Analysts' Ratings History for Oncolytics Biotech (TSE:ONC)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 4/13/2017 | BMO Capital Markets | Boost Price Target | Outperform | C$1.00 -> C$1.50 |  |
| 4/13/2017 | Royal Bank Of Canada | Boost Price Target | Outperform | C$1.00 -> C$1.50 | |
| 8/7/2015 | Canaccord Genuity | Lower Price Target | Buy | C$2.50 -> C$1.75 | |
(Data available from 7/28/2015 forward)
Earnings History for Oncolytics Biotech (TSE:ONC)Earnings History by Quarter for Oncolytics Biotech (TSE ONC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2014 | Q2 14 | ($0.07) | ($0.05) | | | View | N/A | |
| 11/7/2013 | Q3 13 | ($0.07) | ($0.07) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Oncolytics Biotech (TSE:ONC)Current Year EPS Consensus Estimate: $-0.11 EPS
Dividend History for Oncolytics Biotech (TSE:ONC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oncolytics Biotech (TSE:ONC)Insider Trades by Quarter for Oncolytics Biotech (TSE:ONC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/26/2015 | Angela Frances Holtham | Director | Buy | 5,000 | C$0.89 | C$4,450.00 | |
| 5/12/2015 | Wayne Pisano | Director | Buy | 20,000 | C$0.76 | C$15,150.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Oncolytics Biotech (TSE:ONC)
Latest Headlines for Oncolytics Biotech (TSE:ONC)
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA
www.reuters.com - July 27 at 6:04 AM |
 | Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
finance.yahoo.com - July 27 at 6:04 AM |
| Oncolytics (ONCYF) Raises CAD$11 Million
finance.yahoo.com - July 6 at 7:41 AM |
 | Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)
www.prnewswire.com - July 1 at 6:22 AM |
| Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.
finance.yahoo.com - June 30 at 2:53 AM |
| Oncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)
www.prnewswire.com - June 29 at 12:36 AM |
| Today's Research Reports on Oncolytics Biotech, Spectral Medical, CRH Medical and ESSA Pharma
finance.yahoo.com - June 26 at 8:31 AM |
| Oncolytics Biotech® Announces Closing of Public Offering of Units
finance.yahoo.com - June 1 at 7:52 PM |
| IIROC Trade Resumption - ONC.WT
finance.yahoo.com - June 1 at 7:52 PM |
| IIROC Trade Halt - Oncolytics Biotech Inc. Common share purchase warrants
finance.yahoo.com - June 1 at 8:46 AM |
| IIROC Trading Halt - ONC.WT
finance.yahoo.com - June 1 at 8:46 AM |
| Oncolytics Biotech® Prices Public Offering of Units
www.prnewswire.com - May 24 at 7:16 PM |
 | Oncolytics Biotech Prices Public Offering of Units
www.marketwatch.com - May 24 at 7:16 PM |
| BRIEF-Oncolytics Biotech prices public offering of units
www.reuters.com - May 24 at 7:15 PM |
| IIROC Trade Halt - Oncolytics Biotech Inc.
finance.yahoo.com - May 24 at 10:17 AM |
| IIROC Trading Halt - ONC
finance.yahoo.com - May 24 at 10:17 AM |
| Oncolytics Biotech® Announces Proposed Public Offering
finance.yahoo.com - May 23 at 6:31 PM |
| Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017
finance.yahoo.com - May 23 at 10:04 AM |
| Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers
finance.yahoo.com - May 17 at 6:58 PM |
 | FDA Grants Fast Track Status to Oncolytics' Reolysin for Breast Cancer
www.baystreet.ca - May 8 at 12:09 PM |
| BRIEF-Oncolytics Biotech Inc announces FDA fast track designation for Reolysin
www.reuters.com - May 8 at 12:09 PM |
| Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer
finance.yahoo.com - May 8 at 12:09 PM |
| Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)
www.prnewswire.com - May 5 at 7:20 PM |
| Oncolytics Biotech® Inc. Announces 2017 First Quarter Results
www.prnewswire.com - May 5 at 8:53 AM |
 | Oncolytics reports 1Q loss
marketbeat.com - May 5 at 7:18 AM |
| Oncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders - Yahoo Finance
finance.yahoo.com - April 29 at 7:28 PM |
| Oncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders
finance.yahoo.com - April 27 at 10:15 AM |
| ONCYF: REOLYSIN Clinical Development Plan - Yahoo Finance
finance.yahoo.com - April 18 at 6:23 PM |
| ONCYF: REOLYSIN Clinical Development Plan
finance.yahoo.com - April 17 at 6:12 PM |
 | Oncolytics Biotech announces registration pathway and clinical development plan - Seeking Alpha
seekingalpha.com - April 14 at 6:40 PM |
 | Oncolytics Biotech Inc. (ONC) Price Target Raised to C$1.50
www.americanbankingnews.com - April 13 at 4:04 PM |
| Oncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan
finance.yahoo.com - April 12 at 11:54 AM |
| Oncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer
finance.yahoo.com - April 7 at 11:43 AM |
| Oncolytics Biotech Inc. (ONC) PT Set at C$1.00 by Royal Bank of Canada
www.americanbankingnews.com - April 3 at 4:27 PM |
| IIROC Trade Resumption - ONC
finance.yahoo.com - April 3 at 9:30 AM |
| Oncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival …
finance.yahoo.com - March 31 at 7:08 PM |
| IIROC Trading Halt - ONC (all issues)
finance.yahoo.com - March 31 at 7:07 PM |
 | Biopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARC
globenewswire.com - March 28 at 6:48 PM |
| ONCYF: Oncolytic Viruses Emerging as Effective Cancer Treatment
finance.yahoo.com - March 21 at 6:53 PM |
| Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma
finance.yahoo.com - March 16 at 8:47 AM |
| Oncolytics Biotech® Inc. Announces 2016 Year-End Results
finance.yahoo.com - March 10 at 9:16 AM |
| BRIEF-Shanghai Shyndec Pharma's unit fined by food and drug authorities - Reuters
www.reuters.com - March 4 at 12:03 AM |
| Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting
finance.yahoo.com - March 2 at 8:38 AM |
| Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)
globenewswire.com - January 31 at 5:48 AM |
| Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results - Yahoo Finance
finance.yahoo.com - January 29 at 12:10 AM |
| Research Reports Initiated on Healthcare Stocks Oncolytics Biotech, ProMetic Life Sciences, Resverlogix, and Helius Medical Technologies
finance.yahoo.com - January 27 at 12:12 AM |
| Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)
www.prnewswire.com - January 21 at 7:40 AM |
| BRIEF-Oncolytics Biotech names Matt Coffey CEO
www.reuters.com - January 19 at 11:41 PM |
| Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO
finance.yahoo.com - January 19 at 11:41 PM |
| Targovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:53 AM |
Oncolytics Biotech (ONC) Chart for Friday, July, 28, 2017
